The hypothalamic-pituitary-adrenal axis in depression

Depression: From Psychopathology to Pharmacotherapy

Volumn 27, Issue , 2010, Pages 20-31

  Julio Pieper, Marcela ^a   Dinan, Timothy G ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83755222016     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000319427     Document Type: Chapter

References (52)

1. Rubin RT, Dinan TG, Scott LV: The neuroendorinology of affective disorders; in Pfaff D, Arnold AP, Etgen AM, Fahrbach SE, Moss RL, Rubin RT (eds):Hormones, Brain and Behaviour. New York, Academic Press, 2001.
2. de Wied D, Diamant M, Fodor M: Central nervous system effects of the neurohypophyseal hormones and related peptides. Front Neuroendocrinol 1993;14:251-302.
3. Pariante CM, Lightman SL: The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008;31:464-468.
4. Dinan TG, Scott LV: Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat 2005;207:259-264.
5. Aguilera G, Rabadan-Diehl C: Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000;96:23-29.
6. Dinan TG: Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci 1996;58:1683-1694.
7. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-1362.
8. Birnbaumer M: Vasopressin receptors. Trends Endocrinol Metab 2000;11:406-410.
9. McEwen BS: Protective and damaging effects of stress mediators. N Engl J Med 1998;338:171-179.
10. Holsboer F: Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001;62:77-91.
11. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W: Elevated concentrations of CSF corticotropinreleasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-1344.
12. Holsboer F, Von Bardeleben U, Gerken A, Stalla GK, Muller OA: Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984;311:1127.
13. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W, et al: Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314:1329-1335.
14. von Bardeleben U, Stalla GK, Muller OA, Holsboer F: Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pretreatment. Biol Psychiatry 1988;24:782-786.
15. Ur E, Dinan TG, O'Keane V, Clare AW, McLoughlin L, Rees LH, Turner TH, Grossman A, Besser GM: Effect of metyrapone on the pituitary-adrenal axis in depression: relation to dexamethasone suppressor status. Neuroendocrinology 1992;56:533-538.
16. Heuser I, Yassouridis A, Holsboer F: The combined dexamethasone/crh test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.
17. Bardeleben U, Holsboer F: Cortisol response to a combined dexamethasone-human corticotrophinreleasing hormone challenge in patients with depression. J Neuroendocrinol 1989;1:485-488.
18. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996;17:187-205.
19. Himmerich H, Zimmermann P, Ising M, Kloiber S, Lucae S, Kunzel HE, Binder EB, Holsboer F, Uhr M: Changes in the hypothalamic-pituitary-adrenal axis and leptin levels during antidepressant treatment. Neuropsychobiology 2007;55:28-35.
20. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B, Spieler D, Messer T, Lutz R, Kunzel H, Bierner T, Pollmacher T, Pfister H, Nickel T, Sonntag A, Uhr M, Ising M, Holsboer F, Lucae S: Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-Findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009;43:215-229.
21. Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F: The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1085-1093.
22. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL: Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamicpituitary-adrenal axis reactivity. Biol Psychiatry 2009;66:681-685.
23. Gold PW, Goodwin FK, Reus VI: Vasopressin in affective illness. Lancet 1978;i:1233-1236.
24. Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ: Cerebrospinal fluid vasopressin-Changes in depression. Br J Psychiatry 1985;147:696-701.
25. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, De Wied D: Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997;17:284-292.
26. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF: Increased number of vasopressin-and oxytocinexpressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137-143.
27. Meynen G, Unmehopa UA, van Heerikhuize JJ, Hofman MA, Swaab DF, Hoogendijk WJ: Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biol Psychiatry 2006;60:892-895.
28. Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB: Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 1999;84:2238-2240.
29. Muller MB, Landgraf R, Preil J, Sillaber I, Kresse AE, Keck ME, Zimmermann S, Holsboer F, Wurst W: Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 2000;141:4262-4269.
30. Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin v3 receptor responses in melancholic depression. Psychol Med 2004;34:169-172.
31. van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, Sluijs S, Bel-Kacem S, Adolfsson R, Mendlewicz J, Van Duijn C, Deboutte D, Van Broeckhoven C, Claes S: A major SNP haplotype of the arginine vasopressin 1b receptor protects against recurrent major depression. Mol Psychiatry 2004;9:287-292.
32. Dempster EL, Burcescu I, Wigg K, Kiss E, Baji I, Gadoros J, Tamas Z, Kapornai K, Daroczy G, Kennedy JL, Vetro A, Kovacs M, Barr CL: Further genetic evidence implicates the vasopressin system in childhood-onset mood disorders. Eur J Neurosci 2009;30:1615-1619.
33. Linkowski P, Mendlewicz J, Kerkhofs M, Leclercq R, Golstein J, Brasseur M, Copinschi G, Van Cauter E:24-Hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness:effect of antidepressant treatment. J Clin Endocrinol Metab 1987;65:141-152.
34. Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF: 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000;57:755-760.
35. Rubin RT, Poland RE, Lesser IM, Martin DJ, Blodgett AL, Winston RA: Neuroendocrine aspects of primary endogenous depression. 3. Cortisol secretion in relation to diagnosis and symptom patterns. Psychol Med 1987;17:609-619.
36. Wedekind D, Preiss B, Cohrs S, Ruether E, Huether G, Adler L: Relationship between nocturnal urinary cortisol excretion and symptom severity in subgroups of patients with depressive episodes. Neuropsychobiology 2007;56:119-122.
37. Rubin RT, Phillips JJ, Sadow TF, McCracken JT: Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995;52:213-218.
38. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young E: A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22.
39. Carroll BJ: Dexamethasone suppression test: a review of contemporary confusion. J Clin Psychiatry 1985;46:13-24.
40. Thakore JH, Barnes C, Joyce J, Medbak S, Dinan TG: Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res 1997;73:27-32.
41. Lesch KP, Mayer S, Disselkamp-Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM: 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990;28:620-628.
42. Lesch KP, Disselkamp-Tietze J, Schmidtke A:5-HT1A receptor function in depression: effect of chronic amitriptyline treatment. J Neural Transm Gen Sect 1990;80:157-161.
43. Aisa B, Tordera R, Lasheras B, Del Rio J, Ramirez MJ: Effects of maternal separation on hypothalamicpituitary-adrenal responses, cognition and vulnerability to stress in adult female rats. Neuroscience 2008;154:1218-1226.
44. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB: The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008;33:693-710.
45. Carpenter LL, Ross NS, Tyrka AR, Anderson GM, Kelly M, Price LH: Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 2009;34:1208-1213.
46. Laakmann G, Hinz A, Voderholzer U, Daffner C, Muller OA, Neuhauser H, Neulinger E, Wittmann M: The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients. Pharmacopsychiatry 1990;23:18-26.
47. Dinan TG: Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry 1994;164:365-371.
48. Murphy BE: Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997;22(Suppl 1):S125-S132.
49. Thakore JH, Dinan TG: Cortisol synthesis inhibition:a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995;37:364-368.
50. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J: Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999;45:1070-1074.
51. Wolkowitz OM, Reus VI: Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711.
52. Kling MA, Coleman VH, Schulkin J: Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety 2009;26:641-649.